Edition:
United States

Karolinska Development AB (KDEV.ST)

KDEV.ST on Stockholm Stock Exchange

5.05SEK
26 May 2017
Change (% chg)

-0.05kr (-0.98%)
Prev Close
5.10kr
Open
5.05kr
Day's High
5.10kr
Day's Low
4.78kr
Volume
66,819
Avg. Vol
22,009
52-wk High
9.05kr
52-wk Low
4.78kr

Latest Key Developments (Source: Significant Developments)

Karolinska Development Q1 net loss narrow to SEK 25.2 mln
Wednesday, 17 May 2017 01:10am EDT 

May 17 (Reuters) - KAROLINSKA DEVELOPMENT AB ::SAID ON TUESDAY Q1 REVENUE WAS SEK 0.6 MLN VS SEK 0.6 MLN YR AGO.NET LOSS SEK 25.2 MLN VS LOSS SEK 100.1 MLN YR AGO.  Full Article

Karolinska Development: Chairman and CEO to step down, Viktor Drvota new CEO
Thursday, 20 Apr 2017 02:03am EDT 

April 20 (Reuters) - KAROLINSKA DEVELOPMENT AB :KAROLINSKA DEVELOPMENT ANNOUNCES CHAIRMAN BO JESPER HANSEN AND CEO JIM VAN HEUSDEN'S DECISION TO STEP DOWN, AND THE PROMOTION OF VIKTOR DRVOTA TO CEO.CEO, JIM VAN HEUSDEN, WILL FORMALLY LEAVE COMPANY AT END OF OCTOBER 2017..BO JESPER HANSEN, CHAIRMAN, INFORMS THAT HE WILL NOT STAND FOR RE-ELECTION AT 2017 ANNUAL GENERAL MEETING.CEO, JIM VAN HEUSDEN, TENDERS HIS RESIGNATION AND WILL FORMALLY LEAVE COMPANY AT END OF OCTOBER 2017.PROMOTION OF VIKTOR DRVOTA AS COMPANY'S CHIEF EXECUTIVE OFFICER, EFFECTIVE JUNE 1 2017.  Full Article

Karolinska Development announces outcome of set-off issue
Wednesday, 5 Apr 2017 02:01am EDT 

KAROLINSKA DEVELOPMENT AB : REG-KAROLINSKA DEVELOPMENT ANNOUNCES OUTCOME OF SET-OFF ISSUE . CONVERTIBLE HOLDERS ACCEPTED TO OFFSET SEK 67 MILLION OF COMPANY'S CONVERTIBLE DEBT . SHARE CAPITAL WILL INCREASE BY SEK 5.4 MILLION FROM SEK 26.7 MILLION TO SEK 32.2 MILLION .SEB EMISSIONER ACTED AS ISSUING AGENT IN CONNECTION WITH SET-OFF ISSUE.  Full Article

Karolinska Development: research collaboration with Memorial Sloan Kettering Cancer Center
Wednesday, 22 Mar 2017 08:00am EDT 

Karolinska Development AB : Karolinska Development company Aprea Therapeutics announces research collaboration with Memorial Sloan Kettering Cancer Center .Announced a collaboration with Memorial Sloan Kettering Cancer Center to study the effects of reactivation of tumor suppressor protein p53 by APR-246.  Full Article

Karolinska Development: Modus Therapeutics raises SEK 32 mln
Monday, 20 Feb 2017 02:37am EST 

Karolinska Development AB : Karolinska Development company Modus Therapeutics raises 32 million Swedish crowns ($3.5 million)to support development of sevuparin for sickle cell disease .Top-line data from this phase II study is expected in H1 2018.  Full Article

Karolinska Development offers set-off share issue to convertible holders
Tuesday, 7 Feb 2017 01:18am EST 

Karolinska Development AB : Said on Monday will present a proposal to shareholders to approve its decision on a new issue of B-shares to the convertible holders offering the convertible holders to "set-off" their convertibles as payment for new B-shares .Concluded that reducing the convertible debt will lead to a strengthening of the company's equity position and ensuring that its current cash resources can be used to invest in new portfolio companies.  Full Article

Karolinska Development: OssDsign announces new European partnerships
Thursday, 12 Jan 2017 02:00am EST 

Karolinska Development AB : Its portfolio company OssDsign AB announces new European partnerships for commercialization of novel medical implants .OssDsign has entered new commercial partnerships covering distribution of its products in Italy, Spain, Switzerland, Austria and Netherlands.  Full Article

Karolinska Development's Dilafor raises SEK 51 million for study
Tuesday, 27 Sep 2016 02:00am EDT 

Karolinska Development Ab : Karolinska Development portfolio company Dilafor AB raises 51 million Swedish crowns ($6 million) to facilitate phase IIb clinical study with tafoxiparin . Financing has no impact on Karolinska Development's fair value . As a result of new financing, Karolinska Development has decreased its indirect holdings via KDev investments in Dilafor from 53% to 35% .Successful completion of financing round enables Dilafor to facilitate a phase IIb dose finding trial with tafoxiparin trial in northern europe.  Full Article

Karolinska Development Q2 net sales fall to SEK 0.6 mln
Wednesday, 31 Aug 2016 02:42am EDT 

Karolinska Development AB : Net sales amounted to 0.6 million Swedish crowns ($70,000) in Q2 (1.1 million crowns in Q2 2015) .Operational costs in Q2 amounted to 6.6 million crowns, a reduction of 46 pct compared to 12.2 million crowns in Q2 2015.  Full Article

Karolinska Development divests holding in Clanotech to Rosetta Capital
Tuesday, 5 Jul 2016 02:08am EDT 

Karolinska Development AB : Says KDev Investments, investment fund jointly owned by Karolinska Development and Rosetta Capital, will transfer all its shares in Clanotech to Rosetta Capital . Portfolio Net Fair Value will decrease by 54.8 million Swedish crowns ($6.49 million) .Retains an economic interest in company through an earn-out agreement.  Full Article

More From Around the Web